Ann: Market Update, page-251

First 251 Last

Share
Profile

Follow
rona142

4,905 Posts.

261

18/07/19

20:21

Post #: 39589279
Share

Originally posted by crabbe21 ↑

Interesting read from the Dongfang Moderns AGM Presentation.

Bio Health Update16•
Dongfang acquired 70% of Bio Health Pharmaceuticals Pty Limited in 2018; key management retained• Dongfang’s connections and sales network in China open up export opportunities to capitalise on the US$41 billion Chinese health supplements market• Bio Health is a TGA licence holding health supplement (and softgel capsule) manufacturer and Australian Certified Organic licensed business• Strong established customer base with positive reputation for manufacturing high-quality products• Strategic move into high margin, high growth health supplement market broadens Dongfang’s revenue base

Bio Health Update17•
Production in 2018 constrained by size of manufacturing facility• Dongfang is investing in state-of-the art equipment and Bio Health’s move to new site at Huntingwood, Sydney• New facility will enable tripling of current production levels; production expected to begin in second half of 2019• Unit costs expected to reduce by 5% due to economies of scale• Plan allows diversification into health food pharmaceuticals and development of own brand label

Summary18•
Seven consecutive years of record harvest production• Track record of growth and profitability including 2018 net profit after tax of $84.4 million• Australian acquisition of Bio Health provides opportunities to build own brand in high-margin, high-growth health food supplements market• Bio Health is moving to new premises enabling tripling of production; manufacturing at Huntingwood, Sydney expected to begin in second half of 2019• 35% growth in orchard area over past three years, reflecting reinvestment in the business and clear growth strategy • Continued focus on yield improvement in Chinese orchards expected to increase productivity• Ongoing focus on both organic growth and acquisition opportunities• Further revenue growth and profitability expected in 2019

Expand

And how much of that investment in Bio Health has/is actually happening now DFM is suspended and has no board of directors.

CGB Price at posting: 3.7¢ Sentiment: None Disclosure: Not Held
3 Upvote

0 Great analysis

Reply

Top Stories

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

First 251 Last

Add CGB (ASX) to my watchlist

Ann: Market Update, page-251

Top Stories

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Cyclone signs MOU with Vale for development of Iron Bear play

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Featured News